



BLOCK DRUG COMPANY, INC.

257 Cornelison Avenue Jersey City, N.J. 07302-3198
Telephone (201) 434-3000
FAX (201) 332-2362

0167 '01 FEB -7 10:57

Research and Development Laboratories

RICHARD K. BOURNE, Ph.D.
Vice-President - Regulatory Affairs

JAN 25 2001
dyp

January 17, 2001

Charles Ganley, MD
Room S-205; HFD-560
Division of OTC Drug Products
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

RE: Docket 77N-0094 (Salicylamide)

Dear Dr. Ganley:

Reference is made to our request of November 7, 2000 to the subject Docket 77N-0094 for a meeting with the Division to discuss our submission of 1994 and the results of a recently completed pharmacokinetic study which, in our view, provide additional support for reclassification of salicylamide to category I.

Pursuant to the Division's recommendation to withdraw our request for a meeting on the aforementioned subject and the recent acquisition of Block Drug Company by GlaxoSmithKline, we are hereby withdrawing our original request to meet with the Division of OTC Drug Products at this time.

Sincerely,

Richard K. Bourne

Desk Copy:
W. Ellenberg

Encl.
Acknowledgment Copy

77N-0094

LET 139

M E M O R A N D U M

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: 1-30-01


FROM: Director
Division of OTC Drug Products, HFD-560

SUBJECT: Material for Docket No. 71N-0094

TO: Dockets Management Branch, HFA-305

The attached material should be placed on public display under the above referenced Docket No.

This material should be cross-referenced to Comment No. _____


Charles J. Ganley, M.D.

Attachment